Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026

Vinge has advised Folksam Group in connection with two investments in infrastructure funds

Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
October 08, 2026

Vinge has advised Arkivia in connection with a SEK 40 million fundraising

Vinge has advised the legal tech company Arkivia in connection with a fully subscribed share issue of SEK 40 million with new and existing shareholders. The round was led by node.vc. In connection with the share issue, Arkivia also entered into the Swedish Bar Association’s first framework agreement for a case management system.
October 05, 2026